Phase 2 Trial

Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients

Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder

Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder

Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder

Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months

Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months

Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo

Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo

Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events

Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events

Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer

Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer

Phase 2 Trial Recent News

Windtree Reveals Encouraging Data From Istaroxime Study In Early Cardiogenic Shock

Windtree Reveals Encouraging Data From Istaroxime Study In Early Cardiogenic Shock

Windtree Therapeutics Inc (NASDAQ: WINT) has announced positive primary results with istaroxime in rapidly raising systolic blood pressure. Istaroxime is a first-in-class dual mechanism therapy designed to improve systolic and diastolic cardiac function.

Why Acadia Pharma Shares Are Falling Today

Why Acadia Pharma Shares Are Falling Today

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) announced topline results from a Phase 2 trial evaluating the efficacy and safety of ACP-044 for acute pain following bunionectomy surgery.

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study

Genmab A/S (NASDAQ: GMAB) and AbbVie Inc (NYSE: ABBV)

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.

AbbVie Releases New Data From Mid-Stage Navitoclax Combo Trial In Bone Marrow Cancer

AbbVie Releases New Data From Mid-Stage Navitoclax Combo Trial In Bone Marrow Cancer

AbbVie Inc (NYSE: ABBV) has

Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors

Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors

IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma

IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma

IO Biotech Inc (NASDAQ: IOBT)